Kapiva, an Ayurvedic wellness brand, has secured $60 million (around Rs 510 crore) in a Series D funding round led by domestic investor 360 ONE Asset and Singapore-based Vertex Growth fund, a top executive confirmed.
The round also saw participation from existing investors Vertex Ventures Southeast Asia and India, as well as 3one4 Capital, according to co-founder Shantanu, who goes by a single name.
Sources reported in April about Kapiva’s plan to raise this round of funding.
Of the total amount, $28 million comes as primary capital, while the remainder offered an exit to early backers such as Fireside Ventures. The fresh capital will be utilized for research and development, scaling up manufacturing, brand-building initiatives, and strengthening a health-tech ecosystem.
“This funding represents confidence in our vision to make Ayurveda the preferred choice for holistic wellness. Our strong results from clinical trials reflects our commitment to products that are both accessible and proven,” said Kapiva founder Ameve Sharma.
Sharma, a member of the family behind Ayurvedic wellness products maker Baidyanath Group, co-founded Kapiva in 2016 with Shrey Badhani, a former Bain & Co consultant. In 2023, the company promoted its COO Shantanu and CRO Anuj Sharma to co-founder positions.
Kapiva offers a wide range of Ayurvedic products including juices, teas, ghee, honey, vegan protein, oils, and more, spanning categories such as sports nutrition and overall wellness.
“Kapiva’s commitment to scientific Ayurveda—integrating modern science with traditional formulations—has enabled them to create a differentiated product portfolio with strong consumer trust,” said Chetan Naik, Senior Fund Manager and Strategy Head-Technology at 360 ONE Asset. “The wellness industry is experiencing a fundamental shift toward preventive healthcare, and Kapiva’s evidence-based approach focusing on diabetes, hypertension, energy, liver function and other chronic use cases, sets them apart.”
Avendus Capital served as the exclusive financial advisor for the deal.
The company earlier raised $27.4 million in a round led by private equity firm OrbiMed. According to a media report, it also closed an internal funding round of $10 million in 2022.
Back in 2021, it was reported that Kapiva had secured Rs 80-85 crore in a round led by Vertex Ventures, with participation from Fireside Ventures, Jetty Ventures India, and Rishabh Mariwala. Prior to that, in 2019, the company raised $2.5 million in a round led by Fireside Ventures.
Kapiva has since expanded internationally across the Middle East, Europe, and North America, and operates a wholly owned US subsidiary, Kapiva Inc. In India, it follows an omnichannel approach and has a distribution network spanning 40,000 stores.
Kapiva’s steady funding journey and global expansion highlight the growing investor confidence in its mission to make Ayurvedic wellness more accessible and scientifically validated. The brand leverages its diversified product portfolio, omnichannel presence, and evidence-based approach to preventive healthcare to strengthen its leadership in the Ayurvedic wellness industry both in India and abroad.
